Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8662087 | International Journal of Cardiology | 2018 | 6 Pages |
Abstract
There was a significant reduction in LV strain during trastuzumab treatment, which correlated with a concurrent subtle decline in LVEF and was associated with an increase in LV end-diastolic volume. LV strain assessment by CMR may be a promising method to monitor for subclinical myocardial dysfunction in breast cancer patients receiving chemotherapy. Future studies are needed to determine its prognostic and therapeutic implications.
Keywords
GRsNYHANT-proBNPSSFPEDVLVEFhigh-sensitivity troponin IECoGGLSESVCMRN-terminal prohormone of brain natriuretic peptideHER2SPAMMCardiac magnetic resonanceNew York Heart Associationleft ventricleTrastuzumabcardiac magnetic resonance imagingEnd-diastolic volumeend-systolic volumeHARPCardiotoxicityeastern cooperative oncology groupChemotherapyLeft ventricular strainGlobal radial strainGlobal longitudinal strainGlobal longitudinal strain rateleft ventricular ejection fractionHuman epidermal growth factor receptor 2
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Geraldine Ong, Christine Brezden-Masley, Vinita Dhir, Djeven P. Deva, Kelvin K.W. Chan, Chi-Ming Chow, Dinesh Thavendiranathan, Rashida Haq, Joseph J. Barfett, Teresa M. Petrella, Kim A. Connelly, Andrew T. Yan,